Document Detail


Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy.
MedLine Citation:
PMID:  17263633     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Nucleoside reverse transcriptase inhibitors (NRTIs) differ in the type and severity of adverse effects resulting from mitochondrial abnormalities. mtDNA in peripheral blood mononuclear cells (PBMCs) was measured during the first 12 months of different NRTIs combinations and its association with clinical lipodystrophy was estimated. Extended follow-up of a randomized trial, ALBI-ANRS 070, including antiretroviral naive patients was conducted. Total DNA was extracted from available cryopreserved PBMCs at baseline and months 6 and 12. Nuclear and mitochondrial genes were amplified using a real-time PCR assay. Clinical lipodystrophy was assessed 30 months after randomization using a standardized questionnaire. A logistic regression analysis assessed the value of mtDNA to predict lipodystrophy. Mean mtDNA level (copies/cell) significantly decreased from 5847 at baseline to 3176 at month 12 (p < 0.0001). In the zidovudine + lamivudine (ZDV + 3TC) arm (n = 37), the mean mtDNA was 6098, 6807, and 3725 copies/cell for baseline, month 6, and month 12, respectively. In the stavudine + didanosine (d4T + ddI) arm (n = 40), the mean values were 5616, 5731, and 2648 copies/cell, respectively. The proportion of patients in the lowest quartile of mtDNA (<1421 copies/cell) at month 12 was higher in 18 patients with lipodystrophy (44%) than in 28 without lipodystrophy (7%) (p = 0.008). At 12 months, a larger reduction of mtDNA from baseline was observed in those started on the d4T + ddI arm. Furthermore, a low mtDNA level at month 12 was associated with the subsequent development of lipodystrophy. This marker may be of value for the early prevention of lipodystrophy in treated HIV-infected patients.
Authors:
Geneviève Chêne; Bahia Amellal; Gaëlle Pédrono; Karine Gourlain; Corinne Rancinan; Valérie Journot; Laurent Cotte; Pierre Palmer; Nathalie De Castro; Vincent Calvez; Jean-Michel Molina;
Related Documents :
16905783 - Three- vs four-drug antiretroviral regimens for the initial treatment of hiv-1 infectio...
16327333 - Once-daily directly observed therapy lopinavir/ritonavir plus indinavir as a protease i...
22990503 - Cea versus cas: short-term and mid-term results.
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  AIDS research and human retroviruses     Volume:  23     ISSN:  0889-2229     ISO Abbreviation:  AIDS Res. Hum. Retroviruses     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2007-01-31     Completed Date:  2007-04-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8709376     Medline TA:  AIDS Res Hum Retroviruses     Country:  United States    
Other Details:
Languages:  eng     Pagination:  54-61     Citation Subset:  IM; X    
Affiliation:
INSERM, U593, F-33076 Bordeaux, France. genevieve.chene@isped.u-bordeaux2.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-HIV Agents / therapeutic use*
DNA, Mitochondrial / blood*
Didanosine / therapeutic use
Drug Therapy, Combination
Female
Follow-Up Studies
HIV Infections / drug therapy,  pathology
HIV-Associated Lipodystrophy Syndrome / chemically induced,  pathology*
Humans
Lamivudine / therapeutic use
Leukocytes, Mononuclear / chemistry,  metabolism
Logistic Models
Male
Questionnaires
Reverse Transcriptase Inhibitors / therapeutic use*
Stavudine / therapeutic use
Time Factors
Zidovudine / therapeutic use
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/DNA, Mitochondrial; 0/Reverse Transcriptase Inhibitors; 134678-17-4/Lamivudine; 30516-87-1/Zidovudine; 3056-17-5/Stavudine; 69655-05-6/Didanosine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Participation of HIV-infected pregnant women in research in the United States.
Next Document:  Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women...